Health of the Cardinal Inc (NYSE:). shares reached an unprecedented peak, touching an all-time high of $126.3. According to InvestingPro analysis, the stock remains undervalued despite this milestone, highlighting the company’s strong performance amid a challenging healthcare landscape. With a market capitalization of $30.5 billion, Cardinal Health has established itself as a prominent player in the healthcare sector. Last year, Cardinal Health witnessed a significant increase in its stock value, with an impressive increase of 19.61%, including a remarkable 31.87% gain in the last six months. Investors have shown growing confidence in the company’s strategic initiatives and its ability to navigate market changes, pushing the stock to new heights. The company’s GREAT Financial Health Score at InvestingPro further confirming this momentum. Achieving this milestone serves as a testament to Cardinal Health’s enduring strength and potential for continued growth in the competitive healthcare sector. The company’s commitment to shareholder value is proven by its 43-year track record of consecutive dividend payments, which demonstrates remarkable resilience in the dynamic healthcare market.

In other recent news, Cardinal Health raised its full-year earnings forecast for fiscal year 2025, primarily driven by strength within Pharmaceuticals (TADAWUL:) and part of Specialty Solutions. The company now expects non-GAAP EPS to be at the high end of the previously projected range of $7.75 to $7.90. Cardinal Health also announced plans to acquire Integrated Oncology Network for $1.1 billion and plans to acquire a majority equity interest in The GI Alliance Holdings, LLC, and Advanced Diabetes Supply Group. The company successfully raised $2.9 billion through a public offering of senior notes to fund part of these acquisitions.

Cardinal Health’s stock rating was upgraded from Hold to Buy by TD Cowen, with a new price target set at $144. The upgrade is based on the expectation that Cardinal Health will exceed current revenue projections due to new customer acquisitions, strong utilization trends, and recent mergers and acquisitions in specialty services. Evercore ISI upgraded its rating on shares of Cardinal Health from In Line to Outperform, suggesting potential for higher long-term guidance. BofA Securities also upgraded Cardinal Health stock from Neutral to Buy, adjusting the price target upward to $145, anticipating an increase in EPS estimates.

Finally, T2 Biosystems (NASDAQ: ) decided to license its sepsis detection technology after a commercial agreement with Cardinal Health, which aims to improve patient outcomes, reduce mortality rates , and lower healthcare costs by enabling faster, targeted antimicrobial decisions. These are all recent developments that highlight Cardinal Health’s continued growth and strategic initiatives.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.